BioAtla, Inc., a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial public offering of 10,500,000 shares of common stock at a public offering price of $18.00.

All of the shares of common stock are being offered by BioAtla.

Under the ticker symbol “BCAB.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by BioAtla, are expected to be approximately $189.0 million.

The offering is expected to close on December 18, 2020., subject to the satisfaction of customary closing conditions.

BioAtla has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York.